Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
Ashkar R, Feldman DR, Adra N, Zaid MA, Funt SA, Althouse SK, Perkins SM, Snow CI, Lazzara KM, Sego LM, Quinn DI, Hanna NH, Einhorn LH, Albany C. Ashkar R, et al. Among authors: einhorn lh. Invest New Drugs. 2021 Dec;39(6):1656-1663. doi: 10.1007/s10637-021-01134-1. Epub 2021 May 24. Invest New Drugs. 2021. PMID: 34031784 Free PMC article. Clinical Trial.
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ. Motzer RJ, et al. J Clin Oncol. 2007 Jan 20;25(3):247-56. doi: 10.1200/JCO.2005.05.4528. J Clin Oncol. 2007. PMID: 17235042 Clinical Trial.
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.
Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A, Boyle H, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Sava T, Winquist EW, De Giorgi U, Aparicio J, Sweeney CJ, Cohn Cedermark G, Beyer J, Powles T. Feldman DR, et al. Among authors: einhorn lh. J Clin Oncol. 2016 Feb 1;34(4):345-51. doi: 10.1200/JCO.2015.62.7000. Epub 2015 Oct 12. J Clin Oncol. 2016. PMID: 26460295 Free PMC article.
Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.
Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Sesso HD, Fung C, Williams AM, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Zaid MA, Lipshultz SE, Einhorn LH, Oeffinger KC, Travis LB, Fossa SD; Platinum Study Group. Feldman DR, et al. Among authors: einhorn lh. Clin Genitourin Cancer. 2018 Aug;16(4):e761-e769. doi: 10.1016/j.clgc.2018.01.011. Epub 2018 Feb 5. Clin Genitourin Cancer. 2018. PMID: 29534941 Free PMC article.
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group. Abu Zaid M, et al. Among authors: einhorn lh. J Natl Compr Canc Netw. 2019 May 1;17(5):459-468. doi: 10.6004/jnccn.2018.7109. J Natl Compr Canc Netw. 2019. PMID: 31085753 Free PMC article.
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB; Platinum Study Group. Kerns SL, et al. Among authors: einhorn lh. J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4. J Clin Oncol. 2018. PMID: 29617189 Free PMC article.
532 results